Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS

v3.24.2.u1
CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS - USD ($)
12 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2022
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Revenue $ 156,419 $ 8,561 $ 0
Cost of revenue 105,829 9,926  
Gross profit 50,590 (1,365)  
Operating expenses:      
General and administrative 4,594,743 3,552,055 1,299,936
Research & development 1,561,965 2,179,341 433,743
Impairment of intangible asset 390,355    
Total operating expenses 6,547,063 5,731,396 1,733,679
Operating loss (6,496,473) (5,732,761) (1,733,679)
Other income (expense):      
Interest expense, net (26,878) (15,468) (15,438)
Other income (expense) (215,769) 290,466 (753)
Total other income (expense), net (242,647) 274,998 (16,191)
Loss before income taxes (6,739,120) (5,457,763) (1,749,870)
Net loss (6,739,120) (5,457,763) (1,749,870)
Net loss attributable to non-controlling interest (5,583) (269) (41,043)
Net loss attributable to Virax shareholders (6,733,537) (5,457,494) (1,708,827)
Other comprehensive loss:      
Foreign currency adjustment (3,639) (111) (965)
Comprehensive loss (6,735,481) (5,457,652) (1,748,905)
Comprehensive loss attributable to non-controlling interest (5,583) (269) (78,065)
Comprehensive loss attributable to Virax $ (6,729,898) $ (5,457,383) $ (1,670,840)
Basic and diluted weighted average shares outstanding      
Ordinary shares 2,006,414 1,062,984 956,326
Diluted ordinary shares 2,006,414 1,062,984 956,326
Basic and diluted net loss per share to Virax shareholders      
Basic net loss per share - Ordinary shares $ (3.36) $ (5.13) $ (1.79)
Diluted net loss per share - Ordinary shares $ (3.36) $ (5.13) $ (1.79)